Lymphoplasmacytic Lymphoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Non-Hodgkin’s Lymphoma (922)

Waldenstrom Macroglobulinemia (61)

Non-Hodgkin’s Lymphoma (922)

Waldenstrom Macroglobulinemia (61)

›

MYD88 mutation	Waldenstrom Macroglobulinemia	MYD88 mutation	Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: B - Late Trials EHA 2023 - 2 weeks (New B) zanubrutinib Sensitive : B EHA 2023 - 2wk	zanubrutinib Sensitive: B - Late Trials EHA 2023 - 2 weeks zanubrutinib Sensitive : B EHA 2023 - 2 weeks - (New B)
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	ibrutinib + rituximab Sensitive: A1 - Approval ibrutinib + rituximab Sensitive : A1	ibrutinib + rituximab Sensitive: A1 - Approval ibrutinib + rituximab Sensitive : A1
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	acalabrutinib Sensitive: A2 - Guideline acalabrutinib Sensitive : A2	acalabrutinib Sensitive: A2 - Guideline acalabrutinib Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: A2 - Guideline rituximab + ixazomib Sensitive : A2	rituximab + ixazomib Sensitive: A2 - Guideline rituximab + ixazomib Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	fludarabine oral Sensitive: A2 - Guideline fludarabine oral Sensitive : A2	fludarabine oral Sensitive: A2 - Guideline fludarabine oral Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	cladribine Sensitive: A2 - Guideline cladribine Sensitive : A2	cladribine Sensitive: A2 - Guideline cladribine Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	rituximab + bortezomib Sensitive: A2 - Guideline rituximab + bortezomib Sensitive : A2	rituximab + bortezomib Sensitive: A2 - Guideline rituximab + bortezomib Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	ofatumumab Sensitive: A2 - Guideline ofatumumab Sensitive : A2	ofatumumab Sensitive: A2 - Guideline ofatumumab Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	R-CHOP Sensitive: A2 - Guideline R-CHOP Sensitive : A2	R-CHOP Sensitive: A2 - Guideline R-CHOP Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	IRd Sensitive: A2 - Guideline IRd Sensitive : A2	IRd Sensitive: A2 - Guideline IRd Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	FCR Sensitive: A2 - Guideline FCR Sensitive : A2	FCR Sensitive: A2 - Guideline FCR Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	BDR Sensitive: A2 - Guideline BDR Sensitive : A2	BDR Sensitive: A2 - Guideline BDR Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	BR Sensitive: A2 - Guideline BR Sensitive : A2	BR Sensitive: A2 - Guideline BR Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	CaRD Sensitive: A2 - Guideline CaRD Sensitive : A2	CaRD Sensitive: A2 - Guideline CaRD Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	RCD Sensitive: A2 - Guideline RCD Sensitive : A2	RCD Sensitive: A2 - Guideline RCD Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	RCP Sensitive: A2 - Guideline RCP Sensitive : A2	RCP Sensitive: A2 - Guideline RCP Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2
No biomarker	Lymphoplasmacytic Lymphoma	No biomarker	Lymphoplasmacytic Lymphoma	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	CLR 131 Sensitive: B - Late Trials CLR 131 Sensitive : B	CLR 131 Sensitive: B - Late Trials CLR 131 Sensitive : B
No biomarker	Lymphoplasmacytic Lymphoma	No biomarker	Lymphoplasmacytic Lymphoma	CLR 131 Sensitive: B - Late Trials CLR 131 Sensitive : B	CLR 131 Sensitive: B - Late Trials CLR 131 Sensitive : B
MYD88 L265P	Waldenstrom Macroglobulinemia	MYD88 L265P	Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
MYD88 wild-type	Waldenstrom Macroglobulinemia	MYD88 wild-type	Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria rituximab + ixazomib Sensitive : C2	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria rituximab + ixazomib Sensitive : C2
MYD88 L265P	Waldenstrom Macroglobulinemia	MYD88 L265P	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria rituximab + ixazomib Sensitive : C2	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria rituximab + ixazomib Sensitive : C2
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	BDR Sensitive: C3 – Early Trials BDR Sensitive : C3	BDR Sensitive: C3 – Early Trials BDR Sensitive : C3

Lymphoplasmacytic Lymphoma

Associations(63)

Associations
(63)